Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD™ Pivotal Phase 3 Trial in Poland
16354
post-template-default,single,single-post,postid-16354,single-format-link,bridge-core-2.0.9,ajax_fade,page_not_loaded,,qode-theme-ver-19.6,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.2.0,vc_responsive

Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD™ Pivotal Phase 3 Trial in Poland